|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.350 USD | 0.00% |
|
+4.65% | -61.76% |
| 06-30 | ADC Therapeutics SA Completes Enrollment In LOTIS-7 Phase 1b ZYNLONTA Combination Trial | CI |
| 06-30 | ADC Therapeutics Completes Enrollment in LOTIS-7 Lymphoma Study | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ADC THERAPEUTICS SA | Bio Therapeutic Drugs | 0.00% | +4.65% | -61.76% | -56.59% | -94.07% | 172M |
- Stock Market
- Stocks
- ADCT Stock
- Charts ADC Therapeutics SA
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
















